SOURCE: Plandai Biotechnology, Inc.

Plandaí Biotechnology, Inc. Announces Preliminary Results of Study Showing Phytofaretm Catechin Complex Having Ten Times The Greater Bioavailability Than Generic Green Tea Extracts

Greater Bioavailability Allows the Body to Experience More of the Positive Health Benefits of the Green Tea

Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced preliminary results from a human clinical trial conducted by North West University in Potchefstroom, South Africa, which showed the Company’s PhytofareCatechin Complex to have a higher degree of bioavailability – the level of catechin absorption and retention in the blood stream – than generic green tea extracts


According to Prof. Grobler of North West University, when comparing the green tea extract against Phytofare,™ the results showed a ten-fold increase in eight catechins in the blood, where the green tea comparator showed only two detectable catechins. The absorption of Phytofare™ was five times greater than with green tea comparator complexes, while the lifespan of the catechins in the blood was doubled in the case of Phytofare™, resulting in ten-times greater over all bioavailability of the Phytofare™ extract. The comprehensive study results will be posted on the Company’s website:


Catechins are a type of natural phenol and antioxidant, which have been determined to have lipid-lowering, anti-inflammatory, antimicrobial, and antioxidative capabilities.  The study protocol further explains that previous testing of green tea extracts have shown that catechin concentrations peak 1 to 2 hours after ingestion and gradually reduce to undetectable levels after 24 hours.  An extract that allows the body to experience more of the health benefits of green tea is expected to have a significant market advantage over traditional green tea products where most of the catechins are lost through metabolization before they enter the bloodstream.


The non-randomized study, conducted by North West University, used 26 subjects who received generic green tea extract for four days and then had their blood plasma analyzed for a variety of catechins pre-dose and then at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes, 5 hours, 8 hours, 12 hours and 24 hours post-dose.  After a 14-day washout period, the study subjects received a PhytofareCatechin Complex for four days and had their blood plasma analyzed at the same intervals.


A third leg of the study, expected to begin in November, will further examine the bioavailability of a Phytofareentrapped in Pheroid, a patented delivery system licensed from North West University by Plandaí.  Those results will be compared to the data on the generic green tea extract and the PhytofareCatechin Complex.  Entrapment in Pheroid™ is expected to act as a biological stabilizer of the Phytofarecatechins.   The Phytofare™ extract used in the third leg of the study will be processed from tea harvested at Plandaí’s Senteeko estate in Mpumalanga, South Africa


About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.  Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa to producing its proprietary Phytofareextracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.  Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.  For more information, please visit


Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at



Andrew Beyer

Phone: 888-627-6902

Email:  investor@Plandaí



SOURCE: Plandai Biotechnology, Inc.